Voyager Therapeutics Down 15% on End of AbbVie Collaborations
August 03 2020 - 7:21PM
Dow Jones News
By Josh Beckerman
Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours
as the gene therapy company reported the terminations of its tau
and alpha-synuclein vectorized antibody collaborations with AbbVie
Inc.
Voyager retains full rights to the vectorization technology and
certain novel vectorized antibodies developed as part of the
collaborations.
"Through the tau and alpha-synuclein collaborations, we believe
we have made considerable progress against targets for
neurodegenerative diseases," the company said.
Voyager doesn't anticipate any changes to its cash runway
guidance.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 03, 2020 19:06 ET (23:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024